Rapalogs and mTOR inhibitors as anti-aging therapeutics
Open accessThe DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many other compounds that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and maximum life spans. However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans. This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rapamycin and its analogs (so-called ‘rapalogs’) suppress the SASP by inhibiting mTOR and appear to extend healthspan and lifespan in mice105,108,109.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In fact, reviewing the effects of other interventions like rapalogs and sirtuins also shows that they may be impacting many of the similar hallmarks of aging (Lamming et al. 2013, Grabowska et al. 2017).”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Lamming et al. 2013
The cited source says what the claim attributes to it.
In the citing paper
“Many of the side effects of rapamycin, which include immunosuppression, hyperlipidemia and hyperglycemia, have raised concerns about the feasibility of using rapamycin to promote healthy longevity in humans and slowed clinical evaluation of mTOR inhibitors for diseases of aging 26.”
From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [26]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SASP inhibitors (senomorphics) can directly or indirectly attenuate the SASP of senescent cells by inhibiting transcription factor nuclear factor (NF)-κB, the JAK-STAT signal transduction pathway, the serine/threonine protein kinase mTOR, mitochondrial complex-1-related or 4-related targets, or other pathways involved in the induction and maintenance of the SASP103–106.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“no senolytic compounds developed to date are able to eliminate all types of senescent cells; further they retain a low level of toxicity to young normal cells (Lamming et al., 2013).”
From Single senescent cell sequencing reveals heterogeneity in senescent cells induced by telomere erosion (2019) · cites this paper as Lamming et al., 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 2×
“the autophagy-initiating kinase ULK1 (46).”
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 14×
“We might therefore expect other compounds that activate AMPK to specifically inhibit mTORC1 activity.”
BackgroundInfluentialAMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849 · cited 1×
“phorylation of TSC2 and the inhibitory phosphorylation of raptor, an essential component of mTORC1 (92, 93).”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010) · Cell · doi:10.1016/j.cell.2010.02.024 · Cited by 2,464 · cited 1×
“The Rag proteins activate mTORC1 by localizing mTORC1 to the lysosome via interaction with the ragulator complex (110).”
BackgroundSelf-citationProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365 · cited 1×
“This effect was first observed in certain cultured cell lines (73), and we have recently shown that it also occurs in vivo in multiple tissues including liver, muscle, and adipose (see Figure 2).”
BackgroundSelf-citationLaplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170 · cited 1×
“through a wide variety of signaling mechanisms and have roles in many aspects of physiology, which have been reviewed in depth (9).”
BackgroundSelf-citationFranceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M. P., Invidia, L., Celani, L., Scurti, M., et al. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.016 · Cited by 2,087 · cited 1×
“Chronic, low-grade inflammation is a feature of aging, and almost every chronic disease has an inflammatory component (71).”
BackgroundA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · cited 2×
“Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.”
Background
Cited by
Items 201–300 of 565
Effects of senescence on the tumour microenvironment and response to therapy
Reynolds, L. E., Maallin, S., Haston, S., Martínez-Barberá, J. P., Hodivala‐Dilke, K., & Pedrosa, A. (2023) · FEBS Journal · doi:10.1111/febs.16984 · Cited by 45
Nicks, J., Lee, S., Harris, A. B., Falk, D. J., Todd, A. G., Arredondo, K., Dunn, W. A., & Notterpek, L. M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.023 · Cited by 43
Lombardi, A., Gambardella, J., Du, X.-L., Sorriento, D., Mauro, M., Iaccarino, G., Trimarco, B., & Santulli, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-15283-y · Cited by 43
Longevity‐related molecular pathways are subject to midlife “switch” in humans
Timmons, J. A., Volmar, C., Crossland, H., Phillips, B. E., Sood, S., Janczura, K. J., Törmäkangas, T., Kujala, U. M., Kraus, W. E., Atherton, P. J., et al. (2019) · Aging Cell · doi:10.1111/acel.12970 · Cited by 46
“…protein complex (Pan & Finkel, 2017), which regulates “protective” autophagy programs (Yang et al., 2014), and strategies down‐regulating mitochondrial components accompa‐ nied by modest increases in reactive oxygen species (ROS) production (Arriola Apelo et al., 2016; Lamming et al., 2013).”
BackgroundRepurposing drugs to fight aging: The difficult path from bench to bedside
Vaiserman, A. M., Koliada, A. K., Lushchak, O. V., & Castillo, M. J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21773 · Cited by 42
“In different animal models, administration with these agents has been repeatedly demonstrated to delay the onset of age‐related conditions, including endometrial hyperplasia, tendon stiffening, sub‐cellular myocardium changes, liver degeneration, and impairment of physical activity.(71) They are also proved to be effe…”
BackgroundImmune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor γδ T Cells
Dao, V. A., Liu, Y., Pandeswara, S., Svatek, R. S., Gelfond, J., Liu, A., Hurez, V. J., & Curiel, T. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0091 · Cited by 42
“For example, the rapamycin-FKBP12 complex could be influencing calcium flux through ryanodine receptors on γδ T cells to boost function (38).”
BackgroundAnti-Aging Drugs and the Related Signal Pathways
Du, N., Ruigang, Y., Jiang, S., Niu, Z., Zhou, W., Liu, C., Gao, L., & Sun, Q. (2024) · Biomedicines · doi:10.3390/biomedicines12010127 · Cited by 43
PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts
Santis, M. C. D., Sala, V., Martini, M., Ferrero, G. B., & Hirsch, E. (2017) · Cancers · doi:10.3390/cancers9040030 · Cited by 43
“Allosteric inhibitors of mTOR, including sirolimus (rapamycin), everolimus, ridaforolimus, temsirolimus, are licensed therapies for a range of conditions [47].”
BackgroundTargeting Mitochondrial Network Architecture in Down Syndrome and Aging
Mollo, N., Cicatiello, R., Aurilia, M., Scognamiglio, R., Genesio, R., Charalambous, M., Paladino, S., Conti, A. M. F., Nitsch, L., & Izzo, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093134 · Cited by 41
“Numerous studies have shown that rapamycin and some of its analogues (called rapalogues) extend lifespan in yeasts, worms and flies [212], as well as from 10% to 30% in mice [213,214].”
BackgroundNurcahyanti, A. D. R., Jap, A., Lady, J., Prismawan, D., Sharopov, F. S., Daoud, R., Wink, M., & Sobeh, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112138 · Cited by 44
Anti-oxidative cellular protection effect of fasting-induced autophagy as a mechanism for hormesis
Moore, M. N., Shaw, J. P., Adams, D. R. F., & Viarengo, A. (2015) · Marine Environmental Research · doi:10.1016/j.marenvres.2015.04.001 · Cited by 43
Vedova, L. D., Baron, G., Morazzoni, P., Aldini, G., & Gado, F. (2025) · Pharmaceuticals · doi:10.3390/ph18020138 · Cited by 43
Lifespan Modulation in Mice and the Confounding Effects of Genetic Background
Mulvey, L., Sinclair, A., & Selman, C. (2014) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2014.06.002 · Cited by 40
“…complexes: TOR complex 1 (TORC1), which plays a central role in regulating cellular processes associated with growth and differentiation, and TORC2 which has a regulatory role in the insulin signalling cascade (Lamming and Sabatini, 2011; Lamming et al., 2012, 2013; Selman and Partridge, 2012).”
BackgroundRapamycin maintains NAD+/NADH redox homeostasis in muscle cells
Zhang, Z., Xu, H. N., Li, S., Dávila, A., Chellappa, K., Davis, J. G., Guan, Y., Frederick, D. W., Chu, W., Zhao, H., et al. (2020) · Aging · doi:10.18632/aging.103954 · Cited by 44
“lifespan in model organisms ranging from yeast to mice, and a few studies suggest that rapamycin may also promote healthy aging in humans [4, 13, 14].”
BackgroundSelf-citationBarnes, P. J. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-3681-2_3 · Cited by 40
Nutrient sensing of mTORC1 signaling in cancer and aging
Jiang, C., Tan, X., Liu, N., Yan, P., Hou, T., & Wei, W. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.08.001 · Cited by 42
Guan, P., & Wang, N. (2014) · Nutrition · doi:10.1016/j.nut.2013.12.016 · Cited by 39
“The past several years have seen an explosion of interest in the mTOR signaling pathway, spurred in large part by the finding that inhibition of mTORC1 signaling can significantly increase lifespan and protect from age-related diseases in mouse models[10].”
BackgroundIn search of antiaging modalities: Evaluation of mTOR‐ and ROS/DNA damage‐signaling by cytometry
Darżynkiewicz, Z., Zhao, H., Halicka, H. D., Li, J., Lee, Y., Hsieh, T., & WU, J. M. (2014) · Cytometry Part A · doi:10.1002/cyto.a.22452 · Cited by 41
Role of senescence in the chronic health consequences of COVID-19
Wissler Gerdes, E. O., Vanichkachorn, G., Verdoorn, B. P., Hanson, G. J., Joshi, A. Y., Murad, M. H., Rizza, S. A., Hurt, R. T., Tchkonia, T., & Kirkland, J. L. (2022) · Translational Research · doi:10.1016/j.trsl.2021.10.003 · Cited by 38
“Rapamycin and its analogs, rapalogs such as Everolimus or Sirolimus, inhibit mTOR.(131,132) Rapamycin inhibits hyperfunction of the immune system.”
Molecular mechanisms of action of Trehalose in cancer: A comprehensive review
Chaitanya, N. S. N., Devi, A., Sahu, S., & Alugoju, P. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118968 · Cited by 38
Converging Paths of Pulmonary Arterial Hypertension and Cellular Senescence
van der Feen, D. E., Berger, R. M. F., & Bartelds, B. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0329tr · Cited by 40
Soo, S. K., Rudich, P. D., Traa, A., Harris-Gauthier, N., Shields, H. J., & Raamsdonk, J. M. V. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111297 · Cited by 41
Xiao, Y., Zhang, H., Sheng, Y., Liu, F., Gao, J., Liu, G., Li, S., Jiang, N., Yu, C., & Liu, Y. (2022) · iScience · doi:10.1016/j.isci.2022.105539 · Cited by 37
“melanogaster, and mice.(16,17) Furthermore, mTOR acted upstream of PHA-4/FOXA that was essential for lifespan-extending.”
BackgroundExploration of the mechanism and therapy of ovarian aging by targeting cellular senescence
Tang, W., Wang, K., Feng, Y., Tsui, K., Singh, K. K., Stout, M. B., Wang, S., & Wu, M. (2025) · Life Medicine · doi:10.1093/lifemedi/lnaf004 · Cited by 37
“Many studies have found that rapamycin effectively suppresses SASP markers and then inhibits cellular senescence whereas it is now known as one of the top senomorphics that help to mitigate the SASPs secreted by senescent cells, without inducing cell death [197, 198].”
Disruption of the Rag-Ragulator Complex by c17orf59 Inhibits mTORC1
Schweitzer, L. D., Comb, W. C., Bar-Peled, L., & Sabatini, D. M. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.052 · Cited by 33
Self-citationGenetics and Pharmacology of Longevity
Castillo-Quan, J. I., Kinghorn, K. J., & Bjedov, I. (2015) · Advances in genetics · doi:10.1016/bs.adgen.2015.06.002 · Cited by 38
Mukai, S., Ogawa, Y., Urano, F., Kudo‐Saito, C., Kawakami, Y., & Tsubota, K. (2017) · Scientific Reports · doi:10.1038/srep41939 · Cited by 38
“However, it also acts as an immunosuppressive drug and has been reported to induce extensive side-effects such as viral and fungal infections in clinical settings 46,47 .”
Targeting mTORs by omega-3 fatty acids: A possible novel therapeutic strategy for neurodegeneration?
Shirooie, S., Nabavi, S. F., Dehpour, A. R., Belwal, T., Habtemariam, S., Argüelles, S., Sureda, A., Daglia, M., Tomczyk, M., Sobarzo‐Sánchez, E., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.004 · Cited by 38
“In fact, classic mTOR inhibitors such as rapamycin or metformin have been reported to improve the neuronal damage in human and animal models of NDs [12].”
BackgroundPei, T., Huang, X. H., Long, Y., Duan, C., Liu, T., Li, Y., & Huang, W. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.04.012 · Cited by 38
A Systems Biology Roadmap to Decode mTOR Control System in Cancer
Dorvash, M., Farahmandnia, M., & Tavassoly, I. (2019) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-019-00347-6 · Cited by 37
Mohamed, M. A., Elkhateeb, W. A., & Daba, G. M. (2022) · Bioresources and Bioprocessing · doi:10.1186/s40643-022-00554-y · Cited by 37
“The rejuvenative potentials of rapamycin and rapalogues (Guarda et al. 2004; Blagosklonny, 2007; Lamming et al. 2013; Dai et al. 2014; GhasemnejadBerenji 2021) were also suggested to be another reason to use them in reducing severity and impacts of infection with COVID-19 (Husain and Byrareddy 2020; Guarda et al.”
BackgroundAnti-Aging Effect of Traditional Plant-Based Food: An Overview
Das, G., Kameswaran, S., Ramesh, B., Manjunatha, B., Nath, R., Talukdar, A. D., Shin, H., & Patra, J. K. (2024) · Foods · doi:10.3390/foods13233785 · Cited by 37
FoxO1 at the nexus between fat catabolism and longevity pathways
Lettieri‐Barbato, D., Aquilano, K., & Ciriolo, M. R. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.004 · Cited by 37
Implications of Resveratrol on Glucose Uptake and Metabolism
León, D., Uribe, E. A., Zambrano, Á., & Salas, M. (2017) · Molecules · doi:10.3390/molecules22030398 · Cited by 41
“Mammalian target of rapamycin is one of the downstream targets of AMPK, and has an important role as an intracellular nutrient sensor to control protein synthesis, cell growth, proliferation, and metabolism [65,66].”
BackgroundInterventions to slow cardiovascular aging: Dietary restriction, drugs and novel molecules
Heiß, C., Spyridopoulos, I., & Haendeler, J. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.06.015 · Cited by 40
mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels
Goudarzi, K. M., Nistér, M., & Lindström, M. S. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.955743 · Cited by 35
“been reported to inhibit cellular transformation in vitro.(35) On the other hand, compounds that inhibit mTOR including resveratrol, curcumin, and caffeine have been ascribed antioxidant properties, and it was recently described how the antioxidants vitamin E and N-acetylcysteine accelerated lung cancer growth by inhi…”
BackgroundInfluentialWang, J., Zhang, M., & Wang, H. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00284 · Cited by 35
Giudice, G. D., Weinberger, B., & Grubeck‐Loebenstein, B. (2014) · Gerontology · doi:10.1159/000366162 · Cited by 37
Mechanisms of ageing: growth hormone, dietary restriction, and metformin
Khan, J., Pernicova, I., Nisar, K., & Korbonits, M. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00001-3 · Cited by 35
Guaraldi, G., Milić, J., Cesari, M., Leibovici, L., Mandreoli, F., Missier, P., Rozzini, R., Cattelan, A. M., Motta, F., Mussini, C., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101686 · Cited by 34
Wang, Y., Barnett, S. F. H., Le, S., Guo, Z., Zhong, X., Kanchanawong, P., & Yan, J. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b03364 · Cited by 33
Cellular senescence—an aging hallmark in chronic obstructive pulmonary disease pathogenesis
Araya, J., & Kuwano, K. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.09.003 · Cited by 33
Proteostasis and ageing: insights from long‐lived mutant mice
Sands, W. A., Page, M. M., & Selman, C. (2017) · The Journal of Physiology · doi:10.1113/jp274334 · Cited by 32
“…established that the changes that occur during ageing at the level of the phenotype in multicellular organisms is highly conserved, and that ageing rate can be modulated through a number of environmental, genetic and pharmacological means (Gems & Partridge, 2013; Lamming et al. 2013; Selman, 2014).”
BackgroundAutophagy and lysosomal pathways in nervous system disorders
Bingol, B. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.04.009 · Cited by 34
AMPK Inhibits mTOR-Driven Keratinocyte Proliferation after Skin Damage and Stress
Crane, E. D., Wong, W., Zhang, H., O’Neil, G., & Crane, J. D. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.12.036 · Cited by 33
Understanding cellular senescence: pathways involved, therapeutics and longevity aiding
Kumar, A., & Thirumurugan, K. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2287929 · Cited by 31
“…effects are telomerase activators that are used as anti-aging [244], caloric restricted starvation [245], sirtuin activators, inhibitors of mTOR [246], antioxidants [247], agents targeting chemokines, cytokines responsible for chronic inflammation [248], and activators of autophagy [249].”
BackgroundRejuvenating immunity: “anti-aging drug today” eight years later
Blagosklonny, M. V. (2015) · Oncotarget · doi:10.18632/oncotarget.3740 · Cited by 34
“” [14] Now however the same opponent re-invented mTOR-centric model (without appropriate reference), suggesting that “longevity is promoted not via increased insulin sensitivity, but instead via decreased PI3K/Akt/mTOR pathway signaling” [15].”
Immunostimulatory activity of lifespan-extending agents
Pedro, J. M. B., & Senovilla, L. (2013) · Aging · doi:10.18632/aging.100619 · Cited by 34
“The latter encompass the administration of an increasingly wide panel of chemically unrelated molecules, including (but not limited to) resveratrol (a polyphenol found in grapes and red wine), spermidine (a polyamine that is abundant in grapefruits and soybeans), rapamycin (a macrolide originally isolated from the Eas…”
BackgroundmicroRNA-496 – A new, potentially aging-relevant regulator of mTOR
Rubie, C., Kölsch, K., Halajda, B., Eichler, H., Wagenpfeil, S., Roemer, K., & Glanemann, M. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1158360 · Cited by 33
“Potential mechanisms may comprise elevated stress resistance, changes in mitochondrial activity, the modulation of autophagy, effects on stem cell function, and alterations in the spectrum of translated mRNAs.(11,29) mTOR protein itself is regarded as being primarily controlled through post-translational mechanisms.”
BackgroundWang, H., Huang, F., Zhang, Z., Wang, P., Luo, Y., Li, H., Li, N., Wang, J., Zhou, J., Wang, Y., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.32489 · Cited by 31
“Rapamycin and its analogs, such as Everolimus (RAD001) and temsirolimus, allosterically inhibit mTORC1 activity through binding to intracellular FK506 binding protein 12 (FKBP12) receptors(8).”
BackgroundAging: therapeutics for a healthy future
Hodgson, R. A., Kennedy, B. K., Masliah, E., Scearce-Levie, K. A., Tate, B. A., Venkateswaran, A., & Braithwaite, S. P. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.11.021 · Cited by 32
Almendáriz-Palacios, C., Mousseau, D. D., Eskiw, C. H., & Gillespie, Z. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239220 · Cited by 31
“Similarly, the immunosuppressant rapamycin [14] (and the structurally related family of compounds called rapalogs [15]), the polyphenol resveratrol (found in the skin of red fruits, such as grapes) [16,17], and the T2D treatment metformin [18,19] have been examined for their ability to reproduce CR-like effects withou…”
BackgroundMitani, F., Lin, J., Sakamoto, T., Uehara, R., Hikita, T., Yoshida, T., Setiawan, A., Arai, M., & Oneyama, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-10692-0 · Cited by 33
Wang, Q., Yang, L., Hua, Y., Nair, S., Xu, X., & Ren, J. T. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu158 · Cited by 31
“However, chronic exposure of rapamycin may also inhibit mTORC2 (Lamming et al., 2013).”
BackgroundmTOR signalling: jack-of-all-trades
Hiani, Y. E., Egom, E. E. A., & Dong, X. (2018) · Biochemistry and Cell Biology · doi:10.1139/bcb-2018-0004 · Cited by 31
Borsari, C., Keles, E., Rageot, D., Treyer, A., Bohnacker, T., Bissegger, L., Pascale, M. D., Melone, A., SriRamaratnam, R., Beaufils, F., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00620 · Cited by 22
Erfan, O. S., Sonpol, H. M. A., & El‐kader, M. A. (2021) · The Anatomical Record · doi:10.1002/ar.24587 · Cited by 30
“RAPA induces autophagy by inhibiting the mTOR, so block the calcium-dependent and nondependent mTOR signaling pathway (Lamming et al., 2013; Liko and Hall, 2015; Sudarsanam and Johnson, 2010).”
BackgroundDistinct adaptive mechanisms drive recovery from aneuploidy caused by loss of the Ulp2 SUMO protease
Ryu, H., López‐Giráldez, F., Knight, J., Hwang, S. S., Renner, C., Kreft, S. G., & Hochstrasser, M. (2018) · Nature Communications · doi:10.1038/s41467-018-07836-0 · Cited by 30
Teseo, S., Houot, B., Yang, K., Monnier, V., Liu, G., & Tricoire, H. (2021) · Aging and Disease · doi:10.14336/ad.2020.0714-1 · Cited by 32
“Several compounds that interfere with aging pathways, such as metformin or resveratrol, have been proposed as geroprotectors [10, 11].”
BackgroundAntiaging Effects of Dietary Polysaccharides: Advance and Mechanisms
Xu, W., Han, S., Huang, M., Yin, J., Yang, F., & Luo, F. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4362479 · Cited by 30
“Studies have also shown that inhibition of the mTOR signal pathway through gene knockout, treatment with rapamycin, or dietary restriction can delay aging in various biological models such as yeast, worms, fruit fl ies, and mice [91].”
Chrienová, Ž., Rysanek, D., Olekšák, P., Stary, D., Bajda, M., Reiniš, M., Mikyšková, R., Novotny, O., Andrýs, R., Skarka, A., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1048260 · Cited by 28
“However, rapamycin’s inappropriate physicochemical properties and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans (Lamming et al., 2013).”
BackgroundXie, F., Bao, X., Yu, J., Chen, W., Wang, L., Zhang, Z., & Xu, Q. (2015) · Oncotarget · doi:10.18632/oncotarget.4705 · Cited by 30
“com/oncotarget on hemangioma, the underlying mechanism is still unclear [32, 33].”
Caloric restriction and aging stem cells: The stick and the carrot?
Mazzoccoli, G., Tevy, M. F., Borghesan, M., Vergini, M. R. D., & Vinciguerra, M. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.10.014 · Cited by 30
“Anyway, the underlying mechanisms are not completely understood at present, and the increasing number of side effects reported could hinder the employ of rapamycin in humans (Lamming et al., 2013).”
BackgroundThe mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Li, J., Zhu, J., Cao, B., & Mao, X. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990638 · Cited by 31
“Due to the advantage of high specificity, minimal side-effects and clinical approval, the rapalogs have led to trials in which it is combined with other anticancer agents [78].”
BackgroundMarques, A. E. M., Elias, S. T., Porporatti, A. L., CASTILHO, R. M., SQUARIZE, C. H., Canto, G. D. L., & Guerra, E. N. S. (2015) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12390 · Cited by 28
“Molecular deregulation of the mTOR signaling pathway is implicated in human cancer development and progression and is why this protein has emerged as a key target for treating numerous types of cancer (34).”
BackgroundEnergy Metabolism and Metabolic Sensors in Stem Cells: The Metabostem Crossroads of Aging and Cancer
Menéndez, J. A., & Joven, J. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-07320-0_10 · Cited by 27
“Further, treatment with drugs that mimic a state of limited nutrient availability, such as rapamycin, can extend longevity in mice [ 46 – 53 ].”
BackgroundMarine biogenics in sea spray aerosols interact with the mTOR signaling pathway
Asselman, J., Acker, E. V., Rijcke, M. D., Tilleman, L., Nieuwerburgh, F. V., Mees, J., Schamphelaere, K. D., & Janssen, C. (2019) · Scientific Reports · doi:10.1038/s41598-018-36866-3 · Cited by 30
Friend or Foe? Implication of the autophagy-lysosome pathway in SARS-CoV-2 infection and COVID-19
He, W., Gao, Y., Zhou, J., Shi, Y., Xia, D., & Shen, H. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72544 · Cited by 27
“Rapamycin and its analogs (Rapalogs) have been well developed as immune-suppressors, anti-aging and as anti-cancer therapeutics [128, 129].”
BackgroundDerailed Proteostasis as a Determinant of Cardiac Aging
Wiersma, M., Henning, R. H., & Brundel, B. J. J. M. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.03.005 · Cited by 30
“Unfortunately, these derivatives do not only inhibit mTOR activity, but also increase Akt activity, which can drive cancer development.(62) Inhibition of autophagy to counteract CVDs Various CVDs show excessive activation of autophagy (Table 1).”
BackgroundXue, Q., Yang, H., Li, H.-F., Abadir, P. M., Burks, T. N., Koch, L. G., Britton, S. L., Carlson, J., Chen, L., Walston, J. D., et al. (2016) · Aging · doi:10.18632/aging.100929 · Cited by 32
“Although this study was not powered to detect significant difference in mortality (as a secondary outcome) between treatment and placebo groups, the observed improvement in lifespan among the treated, while not statistically significant, is consistent with findings in other vertebrate and invertebrate model organisms…”
ResultKurdi, A., Doncker, M. D., Leloup, A. J. A., Neels, H. M., Timmermans, J., Lemmens, K., Apers, S., Meyer, G. R. Y. D., & Martinet, W. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13626 · Cited by 30
“Everolimus (RAD001) is one of several semisynthetic derivatives of rapamycin, collectively known as rapalogs, with superior pharmacokinetics and pharmacodynamics as compared with the parent compound (Maurizio Salvadori, 2011; Lamming et al., 2013).”
BackgroundXie, Z., Wang, J., Liu, M., Chen, D., Qiu, C., & Sun, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173252 · Cited by 27
Dhokia, V., Albati, A., Smith, H., Thomas, G., & Macip, S. (2024) · Biochemical Society Transactions · doi:10.1042/bst20231066 · Cited by 26
Torin 1 partially corrects vigabatrin‐induced mitochondrial increase in mouse
Vogel, K. R., Ainslie, G. R., Jansen, E. E. W., Salomons, G. S., & Gibson, K. M. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.200 · Cited by 26
“We chose to utilize Torin 1 in lieu of the frequently employed rapalog rapamycin because Torin 1 is highly potent and selective, and several mTORC1 (mechanistic target of rapamycin complex 1) functions are resistant to inhibition by rapamycin, yet effectively blocked by the newer analog Torin 1.(10,11) The GSH Glo glu…”
The role of TORC1 in muscle development in Drosophila
Hatfield, I., Harvey, I. C., Yates, E. R., Redd, J. R., Reiter, L. T., & Bridges, D. (2015) · Scientific Reports · doi:10.1038/srep09676 · Cited by 26
Low-dose antibiotics: current status and outlook for the future
Nosanchuk, J. D., Lin, J., Hunter, R. P., & Aminov, R. I. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00478 · Cited by 32
Arabit, J. G. J., Elhaj, R., Schriner, S. E., Sevrioukov, E. A., & Jafari, M. (2018) · BioMed Research International · doi:10.1155/2018/6726874 · Cited by 28
The therapeutic value of SC66 in human renal cell carcinoma cells
Xu, M., Wang, Y., Zhou, L.-N., Xu, L., Jin, Z., Yang, D., Chen, M., & Zhu, J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2566-1 · Cited by 25
Senotherapeutics for mesenchymal stem cell senescence and rejuvenation
Wong, P., Murugan, D. D., & Ramasamy, T. S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103424 · Cited by 27
Bientinesi, E., Ristori, S., Lulli, M., & Monti, D. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111957 · Cited by 26
“WI-38 cells were plated 8 × 10 3 cells/cm 2 and assessed for SA-β -Gal activity three days after the treatment with quercetin alone or combined with PP242 and 4-PBA, separately.”
MethodInfluentialBajwa, P., Nagendra, P. B., Nielsen, S., Sahoo, S. S., Bielanowicz, A., Lombard, J. M., Wilkinson, J. E., Miller, R. A., & Tanwar, P. S. (2016) · Oncotarget · doi:10.18632/oncotarget.8468 · Cited by 25
“Genetic deletion of the mTor or overexpression of the tuberous sclerosis 1/2 (Tsc1/2) gene significantly increases mean life span in both worms and flies [20].”
BackgroundIslam, M. T., Hall, S. A., Dutson, T., Bloom, S. I., Bramwell, R. C., Kim, J., Tucker, J. R., Machin, D. R., Donato, A. J., & Lesniewski, L. A. (2023) · Aging Cell · doi:10.1111/acel.14040 · Cited by 26
“…interest across many fields, in part due to the ability of rapamycin, a pharmacological mTOR inhibitor, to extend lifespan in various model organisms suggesting that the mTOR signaling pathways can be a target for age-related physiological dysfunction (Harrison et al., 2009; Lamming et al., 2013).”
BackgroundPakravan, N., Mahmoudi, E., Hashemi, S., Kamali, J., Hajiaghayi, R., Rahimzadeh, M., & Mahmoodi, V. (2017) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.12453 · Cited by 28
“Also, a large body of literature attributed anti-aging activities of flavonoids to their potent antioxidant properties.(31,32) Histological comparison of the dermal sections between mice aged 15 months and 2 months revealed that increasing of age is associated by thinner fiber bundles, more open space within and betwe…”
BackgroundAlfatah, M., & Eisenhaber, F. (2022) · GeroScience · doi:10.1007/s11357-022-00598-0 · Cited by 29
Scarpin, M. R., Simmons, C. H., & Brunkard, J. O. (2022) · Journal of Experimental Botany · doi:10.1093/jxb/erac267 · Cited by 24
Zhang, K. S., Schecker, J., Krull, A., Riechert, E., Jürgensen, L., Kamuf‐Schenk, V., Burghaus, J., Kiper, L., Ho, T. C., Wöltje, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53098-1 · Cited by 23
Lifespan-extending interventions induce consistent patterns of fatty acid oxidation in mouse livers
Watanabe, K., Wilmanski, T. M., Baloni, P., Robinson, M., Garcia, G. G., Hoopmann, M. R., Midha, M. K., Baxter, D. H., Maes, M., Morrone, S. R., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05128-y · Cited by 24
Fan, J. J., Chen, C., & Zhong, Y. (2023) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2023.103319 · Cited by 22
Price, K. A. R., & Cohen, E. E. W. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.01.018 · Cited by 24
“Everolimus [79,112]”
Harris‐White, M. E., Ferbas, K. G., Johnson, M. F., Eslami, P., Poteshkina, A., Venkova, K. M., Christov, A., & Hensley, K. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.007 · Cited by 23
“Autophagy is proving so fundamental for tissue maintenance, even in normal tissue, that it has been invoked to explain why caloric restriction reliably slows natural aging (Lamming et al., 2013).”
Chen, X., Hu, X., Li, Y., Zhu, C., Dong, X., Zhang, R., Ma, J., Huang, S., & Chen, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27100 · Cited by 22
Regulation of cardiac miR-208a, an inducer of obesity, by rapamycin and nebivolol
Gul, R., Mahmood, A., Luck, C., Lum‐Naihe, K., Alfadda, A. A., Speth, R. C., & Pulakat, L. (2015) · Obesity · doi:10.1002/oby.21227 · Cited by 22
Targeting Lysosomal Dysfunction and Oxidative Stress in Age-Related Macular Degeneration
Falcão, A. S., Pedro, M. L., Tenreiro, S., & Seabra, M. C. (2025) · Antioxidants · doi:10.3390/antiox14050596 · Cited by 23
“Several derivatives of rapamycin (rapalogs) have been developed, with improved pharmacokinetics [77], which can also emerge as an attractive AMD treatment.”
PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growth in vitro and in vivo
Ye, X., Ruan, J., Huang, H., Huang, W., Zhang, Y., & Zhang, F. (2020) · Aging · doi:10.18632/aging.103221 · Cited by 196
“mTOR, Raptor, mLST8 and several others, required for p70S6K1 and 4EBP1 phosphorylation [15, 22, 23].”
BackgroundMartinović, A., Mantovani, M., Trpchevska, N., Novak, E., Milev, N. B., Bode, L., Ewald, C. Y., Bischof, E. Y., Reichmuth, T., Lapides, R. A., et al. (2024) · Frontiers in Aging · doi:10.3389/fragi.2024.1495029 · Cited by 21
“Inhibition of mTOR has been correlated with lifespan extension in mice and other organisms (Lamming et al., 2013).”
Qin, L., Liang, T., Zhu, X., Hu, W., Li, B., Wei, M., Zhang, J., Li, J., & Wang, J. (2024) · Aging and Disease · doi:10.14336/ad.2024.1404 · Cited by 28
HIV infection and immunosenescence: challenges and intervention strategies
Jin, J., Xu, Q., Zhang, X., Zhu, A., Xia, W., Moog, C., Chan, A. S. W., Zhang, T., & Su, B. (2025) · BMC Medicine · doi:10.1186/s12916-025-04545-6 · Cited by 23
“As a metabolic modulator, metformin alleviates chronic inflammation by activating AMPK and inhibiting mitochondrial complex I, demonstrating potential antiaging effects and advancing into large-scale clinical trials such as the Targeting Aging with Metformin [200, 218, 219].”
Dao, V. A., Pandeswara, S., Liu, Y., Hurez, V. J., Dodds, S. G., Callaway, D. A., Liu, A., Hasty, P., Sharp, Z. D., & Curiel, T. J. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0313-t · Cited by 20
“Whether rapamycin is ultimately the best candidate for human cancerprevention isunclear as legitimate concern for its use anduse of similar agents in large populations has been raised (44).”
BackgroundWoo, J., Shin, S., Ji, H., Ryu, D., Cho, E., Kim, Y. S., Kim, J., Park, D., & Jung, E. (2022) · Nutrients · doi:10.3390/nu14091979 · Cited by 20
“Senomorphics that affect the cellular environment by regulating the SASP through the mTOR inhibitory signals have also been identified [6,30].”
BackgroundNew Trends in Aging Drug Discovery
Benhamú, B., Martín‐Fontecha, M., Vázquez‐Villa, H., López-Rodríguez, M. L., & Ortega‐Gutiérrez, S. (2022) · Biomedicines · doi:10.3390/biomedicines10082006 · Cited by 22
“Better tolerance to exercise and oxygenation ameliorating the lifespan of animals has been demonstrated using senotherapeutic agents such as rapamycin and its analog (rapalog) everolimus [91], metformin [92], SRT1720 [93] (structures shown in Figure 3), and navitoclax (Figure 2B) [94].”
Background
Metadata
- Authors
- Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Pennsylvania (US)
- Broad Institute (US)
- Corresponding author
- Baur, Joseph A.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-03-01
- Volume
- 123
- Issue
- 3
- Pages
- 980-989
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3582126
- OpenAlex
- W2129902630
- Cited by
- 531
- References
- 133
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 42 · 2023: 37 · 2022: 41 · 2021: 25 · 2020: 28 · 2019: 44 · 2018: 46 · 2017: 38 · 2016: 57 · 2015: 61 · 2014: 46 · 2013: 16
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Ellison Medical Foundation
- American Federation for Aging Research
- American Heart Association
- Charles A. King Trust
- Starr Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health
- National Institute on Aging (K99AG041765)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- rapamycin, rapalogs, mTOR inhibitors, anti-aging therapeutics, longevity, lifespan extension, mTOR signaling, genetically heterogeneous mice, adverse drug reactions
- MeSH terms
- Aging, Animals, Anti-Inflammatory Agents, Antineoplastic Agents, Autophagy, Humans, Metformin, Neoplasms, Stem Cells, Sirolimus, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.